You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

11 Results
Guidelines and Advice
Status: Archived
ID: SCT 4
Dec 2012
Guidelines and Advice
Status: In-Review
ID: SCT 3
Mar 2012
Guidelines and Advice
Status: In-Review
ID: SCT 1
Mar 2012
Guidelines and Advice
Status: Current
ID: 8-1
Version: 6
Mar 2024
Guidelines and Advice
Status: In-Review
ID: 12-12-1
Jul 2012
Guidelines and Advice
Status: In-Review
ID: 12-12M
Jul 2012
Guidelines and Advice
Status: Archived
ID: 4-12
Nov 2012
Guidelines and Advice
Status: Archived
ID: 7-19
Oct 2012
Guidelines and Advice
Status: Current
ID: GL 2-21
Version: 2
Mar 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET), according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SUNItinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2024
Drug
Other Name(s): Xpovio®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2024